Neogenomics (NEO) Profit After Tax (2010 - 2026)

Neogenomics (NEO) has reported Profit After Tax for 17 consecutive years, with -$17.1 million the latest figure, recorded in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$17.1 million, up 34.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$99.2 million (down 27.87% YoY), and the FY2025 annual result was -$108.0 million, down 37.22% from the prior year.
• Profit After Tax was -$17.1 million for Q1 2026 at Neogenomics, down from -$9.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$9.9 million in Q4 2025 and troughed at -$49.4 million in Q1 2022.
• Average Profit After Tax over 5 years is -$25.7 million, with a median of -$24.3 million recorded in 2023.
• Year-over-year, Profit After Tax sank 146.53% in 2022 and surged 49.76% in 2023.
• Over 5 years, Profit After Tax stood at -$22.7 million in 2022, then jumped by 36.85% to -$14.3 million in 2023, then declined by 6.97% to -$15.3 million in 2024, then soared by 35.52% to -$9.9 million in 2025, then plunged by 73.12% to -$17.1 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$17.1 million in Q1 2026, -$9.9 million in Q4 2025, and -$27.1 million in Q3 2025.